February 5, 2018 / 9:52 PM / in 10 months

BRIEF-Argos Obtains Option To License PD1 Checkpoint Inhibitors

Feb 5 (Reuters) - Argos Therapeutics Inc:

* ARGOS OBTAINS OPTION TO LICENSE PD1 CHECKPOINT INHIBITORS

* ARGOS THERAPEUTICS INC - ENTERED INTO AN OPTION AGREEMENT WITH PHARMSTANDARD INTERNATIONAL, S.A. AND ACTIGEN LIMITED

* ARGOS THERAPEUTICS INC - UNDER DEAL, CO HAS OPTION TO LICENSE GROUP OF FULLY HUMAN ANTI-PD1 MONOCLONAL ANTIBODIES AND RELATED TECHNOLOGY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below